Antisense RNA has proven a potent inhibitor of gene expression and has the potential to inhibit retroviral replication at a number of stages in the virus life cycle by targeting both viral and cellular RNA sequences. Antisense RNA complementary to three target regions in the 5Ј leader/LTR of human immunodeficiency virus type-1 (HIV-1), the TAR region, the primer binding site and the splice donor (SD)-packaging signal () region were stably expressed from the CMV IE promoter in Jurkat cells, and expression confirmed by RT-PCR. When challenged with HIV-1, cell lines expressing antisense RNA targeting the SD/ region showed significant inhibition of replication (at up to 10 6 TCID 50/ml). These sequences were also expressed in lymphocytes after transduction using recombinant retroviruses and one sequence complementary to the SD/ region inhibited replication of HIV-1. A co-transfection
Introduction
The limitations of combination antiretroviral drug therapies for human immunodeficiency virus type-1 (HIV-1) infection have stimulated research into alternative approaches which complement such therapies. Gene therapy approaches seek to restore immune function using a variety of both protein and RNA effector molecules to inhibit viral replication in CD4 + cells and hence reduce the cytopathic effects of viral infection, or induce the death of infected cells.
1,2 Such therapies may potentially prevent the spread of infectious virus without the toxicity of drug regimens and are likely to require only single, or at least infrequent, applications.
The 5Ј long terminal repeat (LTR) and leader regions of HIV-1 contain a number of cis-acting, non-coding sequences which mediate several essential functions in the viral life cycle. 3 Genomic RNA transcripts which contain all of these sequences have been predicted to form a number of stem-loop structures, including the transactivator response region (TAR) and the major packaging assay using COS-1 cells was also developed both to confirm the antiviral potential of these sequences, and to determine the predominant site of action of these molecules. Antisense RNAs targeting the region and one sequence complementary to the TAR region inhibited expression of viral protein; furthermore, analyses of relative levels of cellular and virion RNA from these assays suggest each of these antisense molecules exerts its effect at an early stage in the transcription-translation pathway, while the longer of the sequences also inhibited packaging of virion RNA. These results suggest that the packaging signal () of HIV-1 represents an attractive target for antisense RNA-based gene therapy, although the main mode of action of such molecules may well be through antisense effects at an earlier stage of replication than packaging. Gene Therapy (2000) 7, 1362-1368.
signal (), modelled by enzymatic and biochemical probing, sequence comparisons and computer modelling. [3] [4] [5] The TAR region is thought to form a 59-nucleotide RNA stem-loop structure which interacts with Tat protein to activate transcriptional elongation via cyclin T and CDK9 phosphorylating RNA polymerase II. 6 Tat is essential for HIV-1 replication and is a potent transactivator of viral gene expression. The primer binding site (PBS) of HIV-1 lies downstream of the U5 region, and consists of an 18-nucleotide sequence which interacts with a tRNA lys3 molecule to prime reverse transcription of genomic viral RNA. 7 Further downstream in the 5Ј leader is a region containing the major packaging signal (), the splice donor (SD) and a putative genomic RNA dimer linkage site (DLS). The HIV-1 packaging signal is multipartite in nature and a major component has been identified as a stem-loop structure immediately upstream of the gag initiation codon. 4 This region interacts with the nucleocapsid protein (p7) subdomain of the Gag polyprotein in a highly specific manner to direct genomic RNA into nascent virions. 8 The DLS, lying upstream of the major packaging signal, mediates dimerisation of viral RNA, a process that may also be facilitated by NC protein. 9 Disruption of interactions between these cis-acting elements and viral proteins or RNA has the potential to down-regulate viral RNA transcription, virion assembly and subsequent reverse transcription in formed virions.
While previous studies have attempted to inhibit viral replication with antisense RNA targeting these regions [10] [11] [12] [13] [14] few have compared the efficacy of different antisense molecules in the same replication assays, or sought to identify the mechanism of the inhibition observed. The purpose of this study was first, to identify antisense sequences complementary to these regions in HIV-1 with optimal inhibitory characteristics, when expressed both by transfected DNA, and by transduced retroviral vectors in CD4 + T lymphocytes. We also attempted to identify the predominant mode of inhibition of viral replication caused by these molecules. In this article we demonstrate significant inhibition of HIV-1 replication by antisense RNA targeting both the TAR and SD/ regions and evidence that the latter may inhibit encapsidation, but that the major antisense effects occur predominantly before translation of viral RNA.
Results
Of the three target regions within the HIV-1 5Ј leader and LTR (TAR, PBS and /SD) one long antisense sequence was designed to target the PBS, and long and short antisense sequences were designed to target TAR and the /SD region ( Figure 1 ). To achieve high-level expression of antisense RNA in lymphocytes an expression vector, pcDNA3.1, utilising the CMV immediate-early promoter was chosen. Once these sequences, designated S1, L1, L2, S3 and L3, were cloned into pcDNA3.1 in both the sense and antisense orientations, each construct, along with pcDNA3.1, was stably transfected into Jurkat T cells. To demonstrate expression of antisense RNA sequences in T lymphocytes cellular RNA from G418-resistant cell lines was extracted and probed by RT-PCR. Figure 2 shows the results of RT-PCRs performed on each of the cell lines expressing antisense RNA along with negative control reactions, indicating that RNA of the appropriate size could be detected in every cell line. Quantitation of RNA expression was attempted by a number of methodologies including RNase protection but the level of expression of all the antisense molecules proved too low to give reliable figures although, in analogous studies, estimates of RNA expression by RT-PCR would suggest a copy number of less than 0.1 per cell and the RT-PCR results gave broadly similar results in all the transfected cells.
To assess potential resistance of cell lines expressing antisense RNA to challenge with HIV-1, cell lines stably expressing pcDNA3.1 constructs were challenged with between 10 4 and 10 6 TCID 50/ml of IIIB virus and sub- sequent viral replication measured by RT assays. Figure  3 shows the results of challenge assays for all of the cell lines generated illustrating that only the cells expressing pcS3A showed significant resistance to HIV-1 replication as compared with control cell lines, although a minor degree of inhibition was noted with L3A. In the case of pcS3A, cell lines also showed substantial resistance up to day 14 at a challenge dose of 10 6 TCID 50/ml. To confirm that resistance to viral challenge was not caused by reduced levels of surface CD4 in these cell lines, CD4 expression was measured by FACS analysis. The expression was found to be similar to control cells (data not shown) confirming that resistance to replication could not be attributed to reduced viral entry via CD4.
A prerequisite to designing antiviral vectors for HIV gene therapy is the ability to deliver antiviral genes to primary T lymphocytes, and recombinant retroviral vectors remain one of the most efficient vehicles for this purpose. A MoMLV-based vector, pBabePuro, 15 was used to produce two different constructs expressing the L3, S3 and L1 sequences as these showed more effect when stably expressed in transfected cells, either as a singlecopy cassette (eg pBS3sc) or as a fusion transcript containing, in addition, the puromycin resistance gene (eg pBS3P): see Figure 4 . The second construct was designed with the intention of increasing both the expression of antisense RNA in target cells and also vector titres of retroviral vector particles through higher expression of vector RNA in producer cell lines. The FLY-A13 producer cell line utilising a MLV amphotropic envelope expressor and MoMLV gag-pol expressor, 16 was used to produce replication-incompetent retroviral particles for transducing Jurkat cells in the first instance. When cell lines stably expressing these constructs were generated in FLY-A13 cells, except for two cell lines, vector titres of only 10 3 to 10 4 c.f.u./ml were obtained: substantially lower than those originally obtained with this cell line. 16 Only cells expressing pBS3sc and pBabePuro itself generated titres higher than this at 5.8 × 10 6 and 1.3 × 10 5 c.f.u./ml, respectively. Attempts to transduce Jurkats with all of the vectors, except pBS3sc and pBabePuro, were unsuccessful for reasons which are unclear, however, the original plasmid constructs were all successfully transfected into Jurkat cells to provide control cells for subsequent viral challenge experiments. Jurkat cells either transduced or transfected with the pBabePuro constructs were challenged with IIIB at identical challenge doses as previously ( Figure 5 ). The cell line transduced with a vector expressing antisense RNA, pBS3sc, showed profound resistance to replication of HIV-1. Stable transfection with the construct pBS3P also showed inhibition of replication on viral challenge. There
Figure 5 Inhibition of viral replication in Jurkat cells transduced with pBabePuro-based antisense vectors (italics) or transfected with pBabePuro antisense constructs (plain text) after challenge with HIV-1 IIIB (10 5 TCID 50s). Reverse transcriptase (RT) activity was measured in cell cultures until 21 days after challenge as described in Materials and methods.
was no significant resistance seen in cells expressing either the L1 or L3 sequences from pBabePuro constructs (data not shown). Thus the S3 sequence consistently inhibited viral replication when expressed in T lymphocytes in a variety of different vectors including transduced or transfected murine retroviral vectors.
We performed, in addition, assays where constructs expressing target sequences in either the 'sense' or antisense orientations, along with pcDNA3.1, were co-transfected with an HIV-1 Gag-Pol expressing construct, LGPH, into COS-1 cells. This was for two reasons. First, suppression of Gag-Pol production in cells co-transfected with antisense constructs would provide supportive evidence of an inhibitory effect of these RNA sequences, in addition to viral challenge assays. Second, analysis of cytoplasmic and virion RNA from cells transfected with these constructs might provide insights into the site of action of antisense RNA sequences in the transcriptiontranslation pathways (and subsequent steps such as RNA packaging in the case of some of the antisense sequences). In the first instance, evidence of suppression of Gag-Pol production by expression of antisense RNA was sought by measuring levels of reverse transcriptase in cell culture supernatants 48 h after co-transfection of plasmids. Figure 6 illustrates the results of the co-transfection assays, showing that, at a 3:1 ratio (antisense:vector DNA), two of the five antisense constructs, L1 and L3, and to a lesser extent S3 inhibited Gag-Pol production (Figure 6a ). When these constructs were co-transfected at variable ratios to the vector construct (Figure 6b ), both L1 and L3 showed a dose-response relationship between the degree of inhibition and amount of antisense-express- ing plasmid transfected. There was a similar, albeit less dramatic trend for S3. These results imply a significant inhibitory effect of the S3, L1 and L3 antisense RNA sequences on the expression of Gag-Pol protein from transfected vector DNA, presumably directly or indirectly due to their antisense action. Assuming the level of RNA transcribed is proportional to the amount of plasmid transfected, the results of co-transfection assays suggest a dose-response for L1 and L3 and not S3 and imply that the inhibitory effect of this latter molecule is maximal at a relatively low level of RNA expression.
Analysis of cytoplasmic and virion RNA from a representative co-transfection experiment by ribonuclease protection assay (RPA) is illustrated in Figure 7 and Table  2 . Although there is a disparity between levels of genomic RNA signal between different control samples (despite equal quantities of cytoplasmic RNA being probed and then loaded) it is still possible to make assessments of the effects of antisense RNA expression on the relative levels of cytoplasmic and virion vector RNA. Relative to 'sense' constructs, there is a striking reduction in signal intensity of genomic RNA from cells expressing each of the antisense RNA sequences, particularly pcL3A and pcS3A. For L1A and L3A this is complemented by a further decrease of encapsidated RNA whereas for S3A, despite the fall in genomic RNA and the fall in RT, the packaging efficiency is, if anything, higher. The apparent decline in cellular RNA might be complicated by antisense RNA complexing with vector RNA, preventing probe binding, as opposed to destroying target RNA, and might be an explanation for this finding. There was also a notable reduction in the intensity of spliced RNA bands for antisense constructs compared with sense, although relative to the amount of genomic RNA, the reductions in spliced RNA do not appear to be significant. Therefore, while it is possible to infer that expression of each of these antisense molecules led to reduced levels of cytoplasmic genomic RNA, it is much less clear whether these RNAs had any specific effect on splicing. Since the antisense RNAs decrease viral particle production more than can be explained by falls in encapsidation and in some cases affect cellular levels of viral mRNA, a significant action of these antisense RNA molecules seems to occur at the level of mRNA processing leading to reduced levels of both genomic and spliced RNA being exported to or surviving in the cytoplasmic compartment. However, in addition, control cells co-transfected with pcL1A and pcL3A both yielded lower levels of virion RNA compared with both their 'sense' controls and 'vector alone' samples, suggesting additional specific inhibitory effects on encapsidation of genomic RNA.
517-nucleotide riboprobe (positions 313-830 of HXB2) was used to hybridise extracted cytoplasmic and virion RNA, and thus enable identification of unspliced genomic RNA (376 nt), singly-spliced RNA (291 nt), 3Ј LTR species (141 nt) and contaminating, transfected DNA (517 nt). Lanes 15 and 16 represent yeast RNA controls with RNase digestion and without digestion, respectively.
Gene Therapy
Discussion
The primary aim of this study was to identify antisense RNA sequences able to suppress viral replication in T lymphocytes as potential antiviral genes for HIV gene therapy. Of the five antisense sequences expressed in Jurkat cells, one, S3, targeting the SD/ region, showed significant antiviral activity in all assays when expressed from both plasmid and retroviral vectors, as well as in a co-transfection assay. Its longer counterpart, L3, showed moderate activity in the initial challenge assays, however, this effect was not repeated when expressed from within a retroviral vector. The superior antiviral effect of L1 compared with S1, in the co-transfection assay, may relate to additional targeting of the U3 region -present at the 3Ј end of all viral RNA transcripts -as has been found in other studies targeting this region, 14 or possibly more effective inhibition of the Tat-TAR interaction. Another possible interpretation may simply be that longer sequences, when optimally expressed (in COS-1 cells), are more efficient at forming stable RNA-RNA duplexes leading to greater inactivation of target mRNAs14. 17 These studies have raised several very important questions about antisense therapy. First, it is important to perform different studies in different model systems in order to optimise the effect. Assessment by co-transfection alone would have given misleading results and might have made it less likely that we would have considered antisense targeting the leader region downstream of the splice donor which, in effect, proved to be a consistent inhibitor of viral replication. Second, these experiments have been done at a level of viral challenge which is considerably higher than those used in other studies. We wished to give our therapeutic molecules the most stringent test available and it is clear that the S3 antisense is capable of providing inhibition even at this very high viral challenge. Given that the particle to infectivity ratio of HIV is something under 10 4 , the S3 antisense is clearly conferring a protective efficacy against an extremely and probably unphysiologically high concentration of infectious particles. Third, we were frustrated and surprised by the low level of expression of all of the antisenses in the cells. They were virtually undetectable by RNase protection which means that they are being expressed at a significantly lower level than common housekeeping cellular messenger RNAs and HIV RNA which we can readily detect in infected cells. Despite this, the comparability of the RT-PCR suggests that the efficacy of the antisense is not purely a function of the level of expression. These findings might suggest that the antisense molecules are actually targeting other mRNAs or that they are exerting their effect in the cells in which they express at a particularly susceptible time/location of virus replication. This extraordinarily low expression together with high efficacy is paradoxically very promising information for future antisense clinical studies.
Antisense RNA has emerged as an important type of inhibitor of HIV gene expression, 14, 18, 19 and one in vivo study, where macaques whose T lymphocytes had been transduced with antisense-expressing vectors and subsequently challenged with SIV, showed considerable promise. 20 One important advantage of antisense RNA over antiviral genes expressing novel proteins such as the RevM10 transdominant negative protein, 21 is that expression of these genes is unlikely to lead to immune responses against cells containing these genes although immune responses against marker genes may be seen if they are present in the transduced construct. 22 In addition, as demonstrated in this study by the efficacy of one antisense sequence less than 100 nucleotides in length, multiple antisense genes could be expressed by one transduced vector.
While it might be argued that the co-transfection assays provide little useful information relevant to the physiological situation (where the ability of CD4 + cells expressing antisense RNA to resist viral replication after challenge is paramount), this assay permits a more rigorous delineation of antisense effects over a single round of 'infection', in addition to providing clues as to the mechanism of action of antisense RNA. The observation that each of the antisense sequences which had suppressed Gag-Pol production in the co-transfection assays reduced levels of both spliced and unspliced cytoplasmic RNA suggests a significant effect on viral RNA before translation, and is consistent with the postulated actions of antisense RNA in disrupting nuclear processing of target RNA and leading to degradation of target sequences by cellular enzymes. 23 It is difficult to draw any firm conclusions about the effect of antisense RNA on subsequent steps in the viral life cycle. If, however, the results suggesting that L1 and L3 specifically inhibit genomic RNA encapsidation are significant, one might conclude that blocking this particular stage of the life cycle requires a longer antisense sequence, possibly more capable of maintaining a stable RNA duplex than shorter sequences. Recent studies examining secondary structure of the SD/ region have supported the concept that there is considerable unwinding of stem loop structures in this region accompanying its interaction with Gag protein 24 and longer antisense sequences may be necessary to prevent their interaction with Gag.
Before vectors expressing antisense RNA can seriously be considered for clinical gene therapy protocols it would be important to demonstrate effective transfer of vectors into primary CD4 + T lymphocytes and resistance of transduced cells to clinical as well as laboratory HIV-1 isolates. As already demonstrated with antiretroviral drugs, targeting multiple stages of the HIV-1 life cycle leads to both reduced viral loads and clinical remission. Antisense RNA molecules targeting several important stages, as yet unapproachable by conventional drug therapy, expressed from a single retroviral vector may be able to induce long-term resistance to viral replication and aid in immune reconstitution.
Materials and methods

Construction of antisense-expressing vectors
Sequences from the HIV-1 molecular clone HXB2, designated S1-L3 ( Figure 1 ) were amplified by PCR using primers containing a HindIII site. The size and positions of these sequences along with the PCR primers used to amplify them are shown in Table 1 . PCR products were digested with HindIII then ligated into the HindIII site of pcDNA3.1 (Invitrogen, Leek, The Netherlands). Recombinants containing these sequences both in the sense and antisense orientations were identified by restriction digestion and sequencing; these constructs were named pcS1A (antisense orientation) and pcS1S (sense orientation) etc. Antisense-expressing vector constructs based on pBabePuro24 15 were constructed as follows (and are illustrated in Figure 4 ). For single-copy vectors, antisense cassettes containing L1, L3 and S3 from the pcDNA3.1-based constructs were excised from these plasmids by digestion with NruI and BamHI and cloned into pBabePuro (linearised with BamHI and SnaBI). Cassettes were removed from the pcDNA3.1 constructs by digestion with NruI and EcoRV including the CMV promoter but no polyA and ligated into the pBabePuro (linearised by NheI). The monocistronic vector, pBS3P, where S3 antisense RNA is expressed as the upstream part of a transcript containing the puromycin resistance (Puro R ) gene from the CMV IE promoter (pCMV), was initially constructed by excision of the SV40 promoter from pBabePuro using BamHI and HindIII. The pCMVantisense cassette from pcS3A was removed by digestion with BglII and EcoRV and cloned into pBabePuro. PCR reactions were performed as for the RT-PCR protocol.
Cell culture, transfection and transduction of vectors Jurkat cells were maintained in RPMI-1640 medium containing penicillin-streptomycin and 10% foetal bovine serum (FBS). Cells were transfected by electroporation at 550 mV and 25 F and selected with either G418 (1.5 mg/ml) or puromycin (0.5 g/ml). Monolayer cells (FLY-A13, COS-1 and NIH 3T3) were grown in Dulbecco's modified eagle medium (DMEM) containing penicillin-streptomycin and supplemented with 10% FBS. COS-1 cells were transfected by the DEAE-dextran method as described previously. 25 pBabePuro-based retroviral vectors were stably transfected into FLY-A13 cells (ATCC CCL81) using Fugene (Boehringer-Mannheim (Roche, East Sussex, UK)) according to the manufacturer's instructions, and once puromycin-resistant colonies were generated antibiotic selection was removed and supernatant from the cultures removed 2 days later. Supernatant was immediately applied either to NIH 3T3 cells (to determine vector titres) or Jurkat cells in the presence of polybrene at 5 g/ml for 4 h, the transduction repeated the following day and antibiotic selection applied 24 h later. Jurkat and FLY-A13 cells were selected with puromycin at 0.5 g/ml, and transduced NIH-3T3 cells selected at 1.5 g/ml. The titre of retroviral vectorcontaining supernatant on NIH-3T3 cells was measured by serial dilution. 16 Antisense and vector RNA detection Total cellular RNA was extracted from Jurkat cells using TRI reagent (Sigma, Poole, UK) according to the manufacturer's instructions. Reverse transcriptase polymerase chain reactions (RT-PCR) were performed using 1 mg of RNA added to a reaction mix consisting of 4 l 5× Reaction Buffer (Promega (Southampton, UK) -250 mm TrisHCl pH 8.3, 375 mm KCl, 15 mm MgCl 2 , 50 mm DTT), 0.8 l dNTPs (25 mm each), 0.4 l primer (25 mm), 20 U RNasin (ribonuclease inhibitor -Promega) and 200 units MoMLV reverse transcriptase, made up to a final volume of 20 l. The reaction mix was incubated at 37°C for 1 h, and the enzyme then inactivated at 95°C for 10 min. For each sample the reaction was performed in duplicate with one reaction not containing the RT enzyme (negative control). Non-transfected cells were also tested as controls (not shown). PCR was performed using a Gene Therapy DNA thermal cycler (Perkin-Elmer Cetus, Norwalk, CT, USA). Reactions consisted of an initial denaturation at 94°C for 5 min followed by 35 cycles of a denaturation step at 94°C for 1 min, an annealing step at 56°C for 1 min and an extension step at 72°C for 1.5 min. A typical 50 l reaction would contain a DNA template, 25 pm of each oligonucleotide primer, 200 mm dNTPs and 1 unit of T. aquaticus DNA polymerase (Taq; Bioline, London, UK) in 1× PCR buffer (Bioline -10 mm Tris-HCL -pH 8.4, 50 mm KCl, 2 mm MgCl 2 , 0.01% gelatin, 0.5% Tween-20, 0.1% Triton X-100) overlayed with mineral oil. DNA templates for PCR were either 10 ng of linearised plasmid DNA (positive control) or 5 l of RT reaction mix products. The primer used for reverse transcription was complementary to the SP6 sequence downstream of the multi-cloning site in pcDNA3.1 (position 989-1010). The second, PCR, stage of the RT-PCR was performed using the same primers (Table 1) originally employed for amplifying the target sequences. Cytoplasmic and virion RNA were extracted from COS-1 cells using the method as previously described. 8 For ribonuclease protection assays (RPA), reactions were performed using the Ambion (Austin, TX, USA) RNase protection assay kit, according to the manufacturer's instructions. Viral particles were normalised by RT activity and cellular message was normalised for total cellular RNA as previously described. 8 The DNA template for synthesis of radiolabelled RNA probes, KSIICS8, 8 was linearised with XbaI producing a 517-nucleotide HXB2-specific riboprobe capable of distinguishing unspliced from spliced HIV-1 transcripts, and transfected plasmid DNA on the basis of the size of protected fragments.
Challenge of Jurkat cells with HIV-1 and RT assays Jurkat cells were challenged with HIV-1 (IIIB) virus stocks in a 96-well format in order to permit large numbers of individual challenges to be performed concurrently at different concentrations of input virus. 10 4 cells in 200 l media were challenged at doses of virus between 10 4 and 10 6 TCID 50/ml. Typically each cell population was challenged at five different doses (4 × 10 6 , 10 6 , 2.5 × 10 5 , 6 × 10 4 and 1.5 × 10 4 TCID 50/ml) with four wells at each concentration. Medium was replaced from cultures twice weekly, and from 7 days after challenge RT levels were calculated from each well twice weekly for three weeks. Reverse transcriptase assays were performed on 10 l samples of cell culture supernatant (in viral challenge experiments), or 10 l of PEG-precipitated supernatant preparation derived from 10 ml of supernatant resuspended in 100 l of PBS (for COS-1 cell cotransfections). The method used for this assay was the mini-RT assay described by Steffens and Gross. 26 RT levels were quantitated on a Packard Beta Counter (Packard Bell, Meriden, CT, USA).
Co-transfection assays in COS-1 cells Antisense constructs were co-transfected with an HIV-1 (IIIB) vector plasmid LGPH expressing all except the env open reading frame of the virus, LGPH, 27 into COS-1 cells at approximately 70% confluence. Transfections were performed in duplicate in 10 cm dishes and 5 g of LGPH was transfected with either 10, 15 or 25 g of antisense or sense-expressing constructs, or pcDNA3.1. Forty-eight hours later supernatant was precipitated with polyethylene glycol (8000) and RT assays were per-formed. For each target sequence three separate experiments were performed where either pcDNA3, the antisense construct or the 'sense' construct were cotransfected with vector DNA (LGPH). Initially, the pcDNA3.1 constructs were co-transfected at a 3:1 ratio (in milligrams of plasmid) to LGPH, however, where there appeared to be a significant inhibitory effect of an antisense construct, the experiments were repeated with additional ratios of 2:1 and 5:1 pcDNA3.1 constructs:
LGPH. In each of these variable ratio co-transfection experiments the total amount of transfected DNA containing the pCMV promoter was kept constant by supplementing antisense or sense constructs with pcDNA3.1. Results from three separate experiments were used to prepare data for mean RT levels for each co-transfection.
